Dr. Andrew Fesnak, MD

Assistant Professor of Clinical Pathology and Laboratory Medicine
University of Pennsylvania Perelman School of Medicine

Contact Information3400 Spruce Street
3 Ravdin Building - R3067
Philadephia, PA, 19104
Office: 215-662-3325

Specialty Division

Transfusion Medicine & Therapeutic Pathology


BA (Molecular Biology), Princeton University, 2005
MD (Medical Doctorate), University of Medicine and Dentistry of New Jersey - Robert Wood Johnson School of Medicine, 2011
MHI (Masters of Health Care Innovation), University of Pennsylvania, 2019

Specialty Certification

Clinical Pathology, American Board of Pathology, 2014
Blood Banking / Transfusion Medicine, American Board of Pathology, 2015
Laboratory Management, Laboratory Management University, American Society for Clinical Pathology, 2015

Postgraduate Training

Resident, Clinical pathology, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, 2011-2014
Research fellow, Immunology, Perelman School of Medicine, University of Pennsylvania, 2012-2015
Clinical fellow, Transfusion medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, 2014-2015
Clinical fellow, Cell therapy, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, 2015-2016

Awards and Honors

Inductee, Gold Humanism Honor Society, 2011
The Kevin E. Salhany, MD Award for Excellence in Clinical Teaching, Department of Pathology and Laboratory Medicine Penn Medicine, 2016

Memberships and Professional Organizations

American Society for Clinical Pathology (ASCP), 2011 - Present
International Society for Cellular Therapy (ISCT), 2011 - Present
AABB, 2011 - Present
College of American Pathologists (CAP), 2011 - 2013
TerumoBCT, 2017 - 2017
Foundation for the Accreditation of Cellular Therapy (FACT), 2018 - Present
American Society for Apheresis (ASFA), 2018 - Present
National Heart, Blood and Lung Institute (NHLBI), 2019 - 2019

Web Links

Selected Publications

Good Manufacturing Practices Facilities for Cellular Therapy

Fesnak A, Levine B, Immunotherapy in Translational Cancer Research, 2018

Robust automated cell counter and viability measurement for engineered T cell product release

Ohayon, Y et al., Cytotherapy 20(5): S195, 2018

Production of chimeric antigen receptor (CAR) T cells

Fesnak A, Suhoski Davis M, Levine B, Nature Protocols 12(4): , 2017

Predictors of Manufacturing (Mfg) Success for Chimeric Antigen Receptor (Car) T Cells in Non-Hodgkin Lymphoma

Davis, M. M., et al., Cytotherapy 19(5): S79-S80, 2017

Considerations in T Cell Therapy Product Development for B cell leukemia and lymphoma immunotherapy

Fesnak AD, Hanley PJ, Levine BL, Curr Hematol Malig Rep, 2017, PMID:28762038

Read article

Showcasing Clinical Development and Production of Cellular Therapies

Levine B, Fesnak A, Riviere I, Mol Ther 25(4): 827-828, 2017

Clinical Development and Manufacture of Chimeric Antigen Receptor T cells and the Role of Leukapheresis

Fesnak A, O'Doherty U, European Oncology and Hematology 13(1): , 2017

CAR-T Cell Therapies From the Transfusion Medicine Perspective

Fesnak, A., Lin, C. Y., Siegel, D. L., Maus, M. V., Transfusion Medicine Reviews 30(3): 139-145, 2016

Immunotherapy with Autologous Cells

Fesnak A, Levine B, Reviews in Cell Biology and Molecular Medicine, 2016

Engineered T cells: the promise and challenges of cancer immunotherapy

Fesnak, A. D., June, C. H., Levine, B. L., Nature Reviews Cancer 16(9): 566-581, 2016

Search PubMed for articles